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t>()'RIGINAL ARTICLE 
I 
NON-CARDIAC SURGERY IN PATIENTS WITH PROSTHETIC 
IIEART VALVES: A 12 YEARS EXPERIENCE 
:'~aja parvez Akhtar, Abdul Rehman Abid,' Hasnain Zalar, Syed Javed Raza Gardezi," Abdul Waheed and Jawad Sajid Khan 
ABSTRACT 
Objective: To study patients with mechanical heart valves undergoing non-cardiac surgery and their anticoagulation 
management during these procedures. 
study Design: It was a cohort study. 
Place and Duration of Study: The study was conducted at the Department of Cardiac Surgery, Punjab Institute of 
. cardiology, Lahore and Department of Surgery, Services Institute of Medical Sciences, Lahore, from September 1994 to 
June 2006. 
patients and Methods: Patients with mechanical heart valves undergoing non-cardiac surgical operation during this 
period, were included. Their anticoagulation was monitored and anticoagulation related complications were recorded. 
Results: In this study, 507 consecutive patients with a mechanical heart valve replacement were followed-up. Forty two 
(8.28%) patients underwent non-cardiac surgical operations of which 24 (57.1 %) were for abdominal and non-abdominal 
surgeries, 5 (20.8%) were emergency and 19 (79.2%) were planned. There were 18 (42.9%) caesarean sections for 
· pregnancies. Among the 24 procedures, there were 7(29.1 %) laparotomies, 7(29.1%) hernia repairs, 2 (8.3%) 
cholecystectomies, 2 (8.3%) hysterectomies, 1 (4.1 %) craniotomy, 1 (4.1 %) spinal surgery for neuroblastoma, 1 (4.1 %) ankle 
fracture and 1 (4.1%) carbuncle. No untoward valve or anticoagulation related complication was seen during this period. 
Conclusion: Patients with mechanical valve prosthesis on life-long anticoagulation, if managed properly, can undergo any 
type of non-cardiac surgical operation with minimal risk. 
KEY WORDS: Rheumatic heart disease. Mechanical heart valves. Non-cardiac surgery. Anticoagulation. 
INTRODUCTION 
·Rheumatic heart disease (RHO) is seen in endemic 
proportions in Pakistan with a prevalence of 5.7/1000.1 A 
large number of these patients are young and present late.! 
Due to recurrent attacks of rheumatic fever (RF), their valves 
are severely diseased.' In majority of patients, these valves 
are not suitable for percutaneous transvenous mitral 
commissurotomy (PTMC) or surgical repair,' and this leaves 
the only option of valve replacement.' Bioprosthetic or tissue 
valves in young patients with rheumatic fever are prone to 
early degeneration and valve failure leading to a revision 
.operation.' Hence, patients are left with mechanical valve 
prosthesis, for which life-long anticoagulation with Warfarin 
is required. 
When patients with mechanical valves require surgery, their 
perioperative management of Warfarin therapy poses a major 
problem.• These patients undergoing non-cardiac surgery 
have a thromboembolic (TE) event rate of 0-2% for aortic valve 
replacement and 11-20% for mitral valve replacement.S-7 
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Kearon et al. have reported a reduction in the incidence of TE 
events at the cost of increased major postoperative bleeds in 
patients receiving intravenous heparin.B Risk of TE is from 
1-22%.9-11 
In order to assess TE and risk of haemorrhage, this study was 
conducted to evaluate the effect of our anticoagulation 
strategy on postoperative outcome of patients with 
mechanical heart valves undergoing non-cardiac surgery. 
pATIENTS AND METHODS 
All the patients who underwent valve replacement with a 
mechanical prosthesis for rheumatic heart disease from 
September 1994 till June 2006 were included in this cohort 
study. They were followed-up regularly in the author's 
outpatient clinic. During follow-up period, their international 
normalized rati.o (INR) and Warfarin dose was monitored and 
yearly echocardiography was done. Anticoagulation related 
events were also recorded . 
Patients with a mechanical heart valve, requiring non-cardiac 
surgical operation for acute or elective procedufe, were 
studied with emphasis to their postoperative outcome. 
Patients were broadly classified as having emergency or 
planned surgery. Patients undergoing emergency surgery 
were admitted under the care of a general surgeon and INR 
was monitored, if it was >2, they were given fresh frozen 
plasma '(FFP) along with Vitamin K. Once the INR was <1.5, 
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surgery was pertormed. 1-'ostoperatlvely, w1thm 6-lL hours, 
patients were restarted on intravenous unfractionated heparin 
(Heparin Leo Pharma UK, 1 millilitre~5000 IU)) [I/V UFH] 
and activated partial thromboplastin time (APIT) was 
monitored 6 hourly with a target of keeping it 2-3 times the 
control. Oral anticoagulation with Warfarin was restarted 
24 hours following surgery and I/V UFH was continued till 
INR was >2.0. Prior to discharge, an echocardiography was 
performed to rule out any clot formation around the 
prosthetic valve or LA. Infective endocarditic prevention 
with intravenous antibiotics was given 6 hours pre-
operatively and for 48 hours postoperatively followed by oral 
antibiotics for 7 days. 
Patients undergoing planned surgery were admitted 36 hours 
pre-operatively and Warfarin was discontinued and their INR 
monitored. Once this was below 2, I/V UFH was commenced 
keeping the APIT 2 times the control and when the INR was 
<1.5, the planned procedure was performed. I/V UFH was 
discontinued 6 hours prior to shifting to the operation room. 
Infective endocarditic prevention was similar to acute group. 
Postoperatively anticoagulation was managed as in the 
emergency group. The same protocol was used in pregnant 
patients the only difference being that they were switched to 
I/V UFH in the last 2 weeks of pregnancy and Warfarin was 
discontinued. 
Once the patient was ambulant, an echocardiography was 
performed to assess the prosthesis for function and formation 
of clot or thrombus. A second echocardiography was done at 
8 weeks. All the patients were followed up till June 2006. 
The data was analyzed by using SPSS 14.0 (Statistical Package 
for Social Sciences Version 14.0) for Windows (SPSS Inc. 
Chicago, 11, USA). Categorical variables were expressed as 
percentages while continuous variables were expressed as 
mean ± standard deviation. Events were defined as 
thromboembolic and hemorrhagic complications. 
RESULTS 
During the study period, a total of 507 patients who had 
undergone mechanical heart valve replacement were followed 
up. The mean age of the study population was 29.5±11.32 
years. There were 292 (57.6%) males and 215 (42.4%) females. 
Two hundred and sixty-eight (52.8%) patients underwent 
prosthetic heart valve replacement for mitral valve disease 
followed by combined mitral and aortic valve disease 96 
(18.9%). Ball and cage valve was most frequently implanted 
345 (68%) followed by bileaflet and single disc valves. Table I. 
All patients were followed up for a total of 2008.5 patient 
years, mean 3.96 ± 3.3 years, median 3.42 years with a range of 
0.16 - 12.08 years. All patients had undergone surgery by a 
single surgeon at the Cardiac Surgery Departinent, Punjab 
Institute of Cardiology, Lahore. In-hospital mortality was 
25 (4.9%) and there were 62 (12.2%) late deaths. At the end of 
12 years, 352 (69.4%) patients were alive and had regular 
follow-up. Seven (1.4%) patients never came for follow-up and 
we were unable to obtain complete follow-up data on 61(12%) 
patients. Forty-two patients had non-cardiac surgery and had 
follow-up during this period. Of these, 24(57.1 %) patients had 
a variety of surgical procedures, among these 5(20.8%) 
underwent emergency and 19 (79.2%) had planned surgery. 
There were 18(42.9%) caesarean sections for pregnancies. 
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tive patients unctergomg acute; emergency opera . 
comprised of 4 females and a male. All female pat; lions 
1 l entshct mitra va ve replacements. Three females und a 
laparotomies, 2 for ectopic pregnancies and 1 for s:r~ent 
oophorectomy. One female underwent craniotomy for Pingo 
intracerebral bleed. qt>e male patient having aortic acute 
replacement and diabetes mellitus underwent Valve 
operation for carbuncle. Nineteen patients had pl acute 
anne· 
operations Table II. a 
Eighteen (42.9%) patients had caesarean sections and had 1. births with no postoperative thromboembolic complicat· IVe Ions. 
There was no episode of thromboembolism (TE) or 
operative bleeding in this series. Two patients ha/ost. 
fu · h · h · · 1 bl one trans swn eac , one Wit mtracrama eed and one W"th 
spinal neuroblastoma. All patients in this study group were
1 
the high risk group forTE due to large LA, AF or having a b;~ 
and cage valve. 
At the end of study period, 2 (4.7%) out of 42 patients died 
one of arrhythmia and the other of renal failure. Th' 
remaining 40 patients had 1300 visits at the author': 
outpatient clinic. The mean INR of these patients was 
2.6 ± 0.47, maintained on a mean warfarin dose of 5.14 ± 1.3. 
DISCUSSION 
Cardiac surgery services are improving in Pakistan with an 
increase in number of centres and open heart surgeries 
performed regularly. More patients with mechanical valve 
prosthesis implanted for rheumatic valve disease will be seen 
over the next few years. This is a relatively young population 
on life-long anticoagulation and will require a non-cardiac 
surgical intervention at some stage. In the West, apart from 
anticoagulation for mechanical valve prosthesis, a large 
number of patients require anticoagulation for non-valvular 
atrial fibrillation and venous thromboembolism.4~ 
The risk of withholding warfarin in patients with mechanical 
valve prosthesis and AF for thromboembolism is high. It has 
been reported to increase to 3.7 fold.4 Whereas Kearon et a/.8 
Table 1: Epidemiological characteristics of the study population. 
Characteristics Total n,so? 
Age mean years 29.5 ±11.32 
Male 292 (57.6%) 
Female 215 (42.4%) 
Diagnosis 
Isolated mitral valve disease 268 (52.8%) 
Isolated aortic valve disease 76 (15%) 
Aortic and mitral valve disease 96 (18.9%) 
Mitral and tricuspid valve disease 45 (8.9%) 
Aortic mitral and tricuspid valve disease 4 (0.8%) 
Aortic valve with IHD 4(0.8%) 
Mitral valve with tHO 2(0.4%) 
Mitral and aortic valve disease with JHD 2 (0.4%) 
Mitral and tricuspid valve disease with IHO 1 (0.2%) 
Mitral valve with other associated lesions like ASD, PFO 9 (18%) 
Prosthesis implanted 
Ball and cage 345 (68%)_ 
Single disc 36 (7.1%J.. 
Bileaflet 126(24.9~ 
IHD= Ischemic Heart Disease; ASD= Atrial Septal Defect; PFO= Patent Foramen Qvale 
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Pi~11. Characteristics of patients undergoing non-cardiac surgery. l ra~l• . 
·_ · ~e sex Valve Non-cardiac Acute/ Adverse 
. _S:No. replaced surgical planned outcome 
- · procedure 
·. ,~ F MVR B&C Laparotomy P Nil 
. I :~ F MVR B&C Laparotomy (SO) P Nil 
•; · 2 - + Hysterectomy 
p Nil '.:.--- 40 F MVR B&C Lumpectomy 
3 breast 
;--~-3~s,___cF _ ___:M::V~R~B:c_&'OC-___:L::,:a:cp::ar_::o:::lo:::m:!.y.:"(E::P-")--':A:_ _ NC"ic_l _ 
·:_·;--- 35 F MVR B&C Cholecystectomy P Nil 
;;·....-- 48 M MVR B&C Hernia P Nil 
. ~ 24 M AVR B&C Hernia P Nil 
7 
•/s!· ____:20:4'--_:F __ M"':':VR::-.:B_::&:::.C _ _,L::a:c:P::ar:::_o:::lo::m"-y-'(E:;P_,)_-':A:-------:'Ni::_l _ 
32 M MVR BV Hernia P Nil 
_:: 10 22 M MVR B&C Hernia P Nil 
, :. jj 38 F MVR+ TV S/0 Hysterectomy P Nil 
_ 12 21 F MVR B&C Laparotomy (SO) A Nil 
13 37 F MVR B&C Hysterectomy P Nil 
14 48 
15 40 
16 45 
17 20 
18 18 
19 30 
20 16 
21 33 
22 26 
23 21 
24 50 
M MVR+AVR Fracture ankle P Nil 
BV 
M 
F 
M 
M 
F 
F 
F 
M 
M 
F 
AVR BV 
MVRBV 
MVR+AVR 
BV 
AVA B&C 
MVR+AVR 
B&C 
MVR BV 
MVR B&C 
MVR B&C 
Carbuncle 
Laparotomy {SO) 
Neuroblastoma 
spine 
Hernia 
Mastectomy 
Craniotomy 
C/S + TL 
Hernia 
MVR+AVR BV Hernia 
MVR+AVR BV LAP CHOLE 
A Nil 
p Nil 
p Nil 
p Nll 
p Nil 
A Nil 
p Nil 
p Nil 
p Nil 
p Nil 
AVA=Aortic valve replacemenl: MVR.=.Milral valve replacement; B&C=Ball and Cage valve; 
BV .. Bileafiet valve: SID,. Single disc valve; FoFemale: M=Male; so .. Salplngo oophorectomy; 
.EP.:Ectopic pregnancy, CIS +TL., Caesarean &ec1kln + 1uballigatkm; Lap CHOLE:Laparoscopic 
c001eetec1omy. 
have shown that of 10,000 patients with mechanical valves 
who are given intravenous heparin, 3 thromboembolic 
episodes are prevented at the risk of 300 major postoperative 
bleeds.' 
Gohlke~Barwolf et ars have shown that the risk of TE varies 
from 0~2% in AVR and 11 - 20 % in MVR.S Prendergast eta/. 
have shown that the risk of TE for patients with prosthetic 
valve without anticoagulation is from 8-22% per annum and 
0.02-0.06% per day.' Withholding anticoagulation to a sub~ 
therapeutic level has a theoretical risk of TE of 0.08~0.36%.9 
This may be even higher depending upon rhythm, type of 
prosthesis, LA size, LV function and previous history of TE.' 
The occlusion of prosthetic valve has been reported to occur 
in 1~13% of cases.1o There is an approximately 4~8 per 100 
patient~year rate of major thromboembolism in patients not 
receiving long~tenn anticoagulation therapy.n Factors which 
predispose to an increased risk of thromboembolism include 
number of valves placed, type of valve implanted (greater in 
ball and cage variety), mitral valve replacement, atrial 
fibrillation, left atrial enlargement, LV dysfunction, dotting 
disorder and prior embolic event.12 
ln this study of 507 patients, 42 underwent non~cardiac 
surgical operations; 5 were emergency; 19 were planned 
operations and 18 were caesarean sections. This was a 
challenge as it involved a multidisciplinary approach in 
collaboration with another hospital smgical team. Larson 
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et a!.13 and Douketis et al.l4 have described in their articles that 
there is no consensus regarding the management of 
perioperative anticoagulation in these patients.13,14 This is 
largely due to lack of clinical trials investigating different 
strategies.!' The most commonly used strategy is to admit the 
patient 3-4 days pre~opera!~vely, discontinue their Warfarin 
monitor INR once below therapeutic range start IV UFH.13 
This is stopped 3 hours before surgery, 1/V UFH is restarted 
6-12 hours after surgery along with oral warfarin therapy. The 
incidence for postoperative major bleeding has been reported 
as 10.9% with low molecular weight heparin (LWMH), 12.1% 
with UFH.13 There was no episode of thromboembolism, 
valve thrombosis or haemorrhage in this series. Heparin is 
continued till INR is in therapeutic range. 
It has been reported by some that the risk of TE is exaggerated 
and IV heparin should only be used in patients with previous 
history of TE. A less aggressive approach is temporary 
discontinuation of warfarin and substituting it with 
subcutaneous UFH or LMWH. Authors do not agree with this 
as patients included in this study are at high risk of TE and 
anticoagulation was sub-therapeutic due to the reasons 
mentioned above. 
Ansell et aJ.l5 in their article have recommended that patients 
with a high risk of TE should withhold warfarin 4 days prior 
to surgery and allow the INR to fall below the therapeutic 
range and commence the patients on full dose heparin or 
LMWH and to stop this 3-6 hours before the surgery. In this 
studym the INR levels was maintained on the lower 
therapeutic range (2~2.5) thus the admission 24~36 hours pre~ 
operative is sufficient and in planned surgeries their warfarin 
dose was reduced a week before surgery. On admission, their 
INR was around 1.8~2.2; I/V UFH was started and warfarin 
was omitted, once INR was <1.5, they underwent surgery. 
Reduced pre-operative admission time was thus seen. 
Authors agree with Gohlke~Barwolf et af.S that for major 
surgery, it is required to lower the INR to <1.5 and 1/V UFH 
commenced once INR was <2 and APTI should be maintained 
at 1.5 ~ 2 times the control. Heparin is held 3-6 hours prior to 
surgery and to restart it 6~12 hours postoperation with an aim 
to keep APTI 2 times normal. Warfarin is restarted 24 hours 
postoperatively or when patients can start oral intake. With 
this regime in this cohort, no postoperative hemorrhagic or 
thromboembolic complication was seen. Goldman et aJ.16 have 
reported a high risk of bleeding postoperatively and have 
stressed on lowering the INR to avoid hemorrhagic 
complications.l6 
In case of emergency surgery, the affect of warfarin needs to be 
neutralized by FFP, the dose of which depends upon the 
individual and this is titrated till INR was <1.5. In addition to 
this, vitamin K may also be given intravenously in small doses 
as large doses may lead to resistance to warfarin once, it is 
restarted following surgery.s 
In patients who were pregnant and undergoing caesarean 
section, they were admitted and their warfarin was 
discontinued two weeks prior to the due date and they were 
commenced on 1/V UFH and APTI was kept at 2~3 time the 
normal. The recommendations of European Society of 
Cardiology" and American College of Cerdiology" for 
anticoagulation during pregnancy in patients with prosthetic 
valves to be opted after discussion with the patient and 
spouse. 
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Oh et af.l8 have reported a survey conducted by Korean 
physicians regarding 4 different scenarios and a questionnaire 
was sent "With four treatment options in each scenario. Their 
answers showed a substantial variability. A similar survey by 
the Canadian Society of Internal Medicine was carried out,14 
which showed that the most frequent regime was pre and 
post-operative 1/V UFH therapy. Intensity of anticoagulation 
was influenced by the risk of TE and not haemorrhage in both 
the surveys. 
Warfarin recommendations by Amercian Heart Association 
and British Committee for Standards in Haematology have 
also emphasized optimization of anticoagulation therapy in 
patients of mechanical heart valves undergoing non-cardiac 
surgery.I9-21 
Authors agree with the recommendations given by Sridhar 
"aJ.4 and broadly follow that protocol. The only modification 
recommended is in planned surgery, the dose of warfarin can 
be tapered one week prior to the planned date of admission as 
descussed earlier. 
CoNcLUsiON 
Patients with mechanical valve prosthesis, on life-long 
anticoagulation, if managed properly, can undergo any type of 
non-cardiac surgical operation with minimal risk. 
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